title: Remission induced by a new specific oral polymeric diet in children with Crohn's disease.
abstract: We have been able to show that CT3211 is an effective oral treatment in children with active Crohn's disease. It was well tolerated, and there were minimal side effects. At the mucosal site of disease there was macroscopic and histological improvement, together with evidence of downregulation of the pro-inflammatory cytokines IL-1 beta, IL-8, and IFN-gamma.
authors.affiliation: Chelsea and Westminster Hospital, London, UK.
authors.forename: J M
authors.initials: JM
authors.lastname: Fell
authors.forename: M
authors.initials: M
authors.lastname: Paintin
authors.forename: A
authors.initials: A
authors.lastname: Donnet-Hughes
authors.forename: F
authors.initials: F
authors.lastname: Arnaud-Battandier
authors.forename: T T
authors.initials: TT
authors.lastname: MacDonald
authors.forename: J A
authors.initials: JA
authors.lastname: Walker-Smith
mesh_terms: D000293:Adolescent; D002364:Caseins / Q000008:administration & dosage; D002648:Child; D015331:Cohort Studies; D003424:Crohn Disease / Q000178:diet therapy*; D005260:Female; D005526:Food, Formulated / Q000032:analysis / Q000592:standards; D006801:Humans; D008297:Male; D010349:Patient Compliance; D011446:Prospective Studies; D012074:Remission Induction; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D053781:Transforming Growth Factor beta2; D016896:Treatment Outcome
chemical_list: D002364:Caseins; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2